Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Loading...
November 23, 2023
Dr Ben Swift has been awarded a Horizon award by AMI for his ground-breaking work developing a phage-based diagnostic for tuberculosis.
November 23, 2023
Dr Ben Swift has been awarded a Horizon award by AMI for his ground-breaking work developing a phage-based diagnostic for...
November 14, 2023
Grant of a patent has been awarded to PBD Biotech for its Actiphage diagnostic for incipient tuberculosis in South Africa, this complements the regional West Africa patent gained earlier this year.
November 14, 2023
Grant of a patent has been awarded to PBD Biotech for its Actiphage diagnostic for incipient tuberculosis in South Africa, this complements...
November 10, 2023
The Translational Microbiology Prize is awarded to an individual who has demonstrated an outstanding contribution to translational microbiology.
The Translational Microbiology Prize is awarded to an individual who has demonstrated an outstanding contribution to translational microbiology.
October 27, 2023
PBD Biotech has been working closely with the R2D2 TB Network to set up the trial protocol for its Actiphage® tuberculosis diagnostic, and the first test kit is being dispatched.
PBD Biotech has been working closely with the R2D2 TB Network to set up the trial protocol for its Actiphage®...
5 October 2023
September 26, 2023
PBD Biotech is one of the finalists selected to participate in the 42plus1 pitch event at DxPx EU in Munich, Germany on the 5th October 2023. This follows our participation in DxPx US.
PBD Biotech is one of the finalists selected to participate in the 42plus1 pitch event at DxPx EU in Munich,...
September 19, 2023
Conventional phase 3 trials do not provide key information about the overall effect of introducing a new tuberculosis vaccine programme and so are missing crucial information for policy makers, argue experts in a personal view in Lancet Microbe.
Conventional phase 3 trials do not provide key information about the overall effect of introducing a new tuberculosis vaccine programme...